On September 26, 2025, bioAffinity Technologies, Inc. (NASDAQ: BIAF) announced the release of three new case studies that illustrate the clinical effectiveness of its CyPath Lung test. The case studies show that CyPath Lung detected Stage 1A lung cancer or prevented unnecessary invasive procedures, reinforcing the test’s potential for early detection and supporting ongoing reimbursement discussions.
CyPath Lung is a sputum‑based, flow cytometry and AI‑driven diagnostic test that identifies early‑stage lung cancer. The new case studies demonstrate the test’s ability to detect cancer at the earliest stage, potentially improving patient outcomes and reducing healthcare costs associated with invasive diagnostics.
By adding these case studies, bioAffinity strengthens its evidence base for CyPath Lung, which may accelerate adoption by clinicians and payers. The company expects that the expanded clinical data will support future regulatory submissions and market expansion, potentially enhancing revenue growth for its flagship product.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.